See how reported total compensation, cash compensation, and equity mix change as biotech companies progress from clinical development toward commercialization.

Executive compensation does not move in a straight line across biotechnology companies. A clinical-stage company, a business preparing for launch, and a commercial organization place different demands on the CEO and CFO roles. This concise report uses source-traceable public-company disclosures to show how compensation changes across those operating stages.